Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse potential of samidorphan in recreational opioid users
NCT02218021Phase 1Completed
- Sponsor
- Alkermes
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of samidorphan in opioid use disorder (OUD), alcohol use disorder (AUD), schizophrenia and 1 more (6 arms), sponsored by Alkermes. Primary endpoint: Abuse potential measured by visual analog scales at 4 weeks. Started Aug 2014; status: completed.
02
Drugs
samidorphan
03
Conditions
opioid use disorder (OUD)alcohol use disorder (AUD)schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT02218021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02218021.